The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more

Summit Therapeutics' two co-CEOs bought a massive $100M of stock at the lows, and insiders keep buying, a sign something is cooking. After a 30% fall over the past year the shares are cheap, and cheap is when to buy. x.com  x.com 

Ionis is best avoided because major Phase 3 trials still hang over it, making it hard to size a meaningful position while controlling risk. Biotechs can drop 10-30% overnight on a negative read-through from another company's similar drug, with no chance to react, and a 1-2% position is mostly a waste of time. Biotech names are worth owning only once profitable, generating real cash and free of major Phase 3 risk. x.com 

Moderna is not a long here because its valuation is now super stretched after a huge one-day move. Per @A_May_MD, Moderna added $45B in market cap on a dataless phase 3 press release in adjuvant combination melanoma, with a drug it owns only half of. Non-experts expecting AI to cure cancer and develop drugs at insane speed are out of their league. The news is great, but risk needs managing, and this may work only as a trade. x.com  x.com  x.com  x.com  x.com 

Summit Therapeutics' ivonescimab looks materially de-risked after beating Keytruda on overall survival. Partner Akeso said ivonescimab monotherapy showed a statistically significant survival benefit over Keytruda in PD-L1+ advanced lung cancer in China's Phase III HARMONi-2 trial, the first drug to do so head-to-head, answering the global HARMONi survival miss ahead of a November 14 FDA decision date. Insider buying, notably by Robert Duggan, and large short interest add to the setup. x.com  … Show more

Summit Therapeutics' leaders bought at the lows, a strong signal ahead of the November 14 FDA decision date for ivonescimab. Co-CEO Robert Duggan bought 3.81M shares twice at $13.12, about $100M, the same week Summit pulled a $500M stock offering, choosing personal cash over dilution. Phase 3 HARMONi-6 showed ivonescimab cut the risk of death 34% versus tislelizumab combinations in first-line squamous NSCLC. A pennant breakout above $15.88 could run toward the $20s. x.com  x.com